Hindustan Bio Sciences Ltd

AGM details

• AGM held 30 Sep 2026, 10:00–10:45 AM, physical at registered office.
• Cut-off date for voting: 23 Sep 2026.
• Total shareholders on record: 12,039.
• E-voting window: 27 Sep 2026 to 29 Sep 2026.
• Agenda included adoption of financial statements and related reports.

Key resolutions and outcomes

• Resolution 1: Adopt audited financial statements for year ended March 31, 2026; Status: Passed.
• Resolution 2: Re-appointment by rotation of Smt. Uma Jampana.
• Resolution 3: Special resolution to reduce share capital.

Director changes

• Director changes: Smt. Uma Jampana re-appointed by rotation.

Observations

• No substantive AGM resolutions disclosed in this excerpt; only signing metadata present.

Hindustan Bio Sciences Ltd — Closure of Trading Window

Financial performance

• Revenue from operations: Rs 73.71 Lakh in 2025-26, down from 81.33 Lakh in 2024-25.
• Profit after tax: Rs -7.89 Lakh in 2025-26, vs Rs 10.07 Lakh prior year.
• EPS: Basic/Diluted Rs -0.08 in 2025-26; Rs 0.10 in 2024-25.
• Total expenses Rs 81.64 Lakh in 2025-26, up from Rs 71.51 Lakh.
• Export revenue contributed Rs 70.44 Lakh in 2025-26.
• Dividend: No dividend recommended for FY 2025-26.

Geography and operations

• Exports revenue Rs 70.44 Lakh; Domestic sales nil.
• No change in business nature during the year.

Capital restructuring

• Notice includes Scheme of Reduction of Share Capital.
• Post-scheme paid-up capital: 9,22,572 shares of Rs 10 each.
• Authorised capital remains Rs 11 crore; new par value Rs 10.
• Accumulated losses of Rs 1,12,75,880 written off against paid-up capital.
• Fractions rounded up; promoter to forego rounding.

Debt, liquidity and capital allocation

• Long-term borrowings Rs 234.95 Lakh; no short-term borrowings.
• Total assets Rs 319.54 Lakh; net worth Rs 82.60 Lakh.
• Debt/Equity ratio 2.84x.
• Cash and cash equivalents Rs 13.03 Lakh at year-end.

Governance and audit

• Statutory auditors: VASG & Associates; no reservations.
• Secretarial auditor: VBSS Prasad; board-approved compliance program.
• Board comprises six directors; three independent; independence confirmed.
• CEO/CFO certifications aligned with SEBI LODR requirements.

Related party transactions

• Loans and advances from related parties include Rs 181.35 Lakh from JVR Mohan Raju.
• Rs 36.99 Lakh from Nipuna Shelters; Rs 5.61 Lakh from Super Solutions.
• 03 Lakh from Uma Jampana (net).
• KMP remuneration: Rs 9.60 Lakh; MD Rs 6.00 Lakh.

AGM and corporate actions

• AGM date: 30-09-2026; venue: registered office; remote e-voting offered.
• Book closure: 24-09-2026 to 30-09-2026.
• Notice and annual report uploaded on company website; proxies permitted.

Risks and outlook

• Outlook constrained by delays in Sri Lanka regulatory licences.
• Timely license renewals could restore capacity and revenue.

Capital reduction approved

• Board approved Scheme of Reduction of Capital under Companies Act 2013.
• Approval subject to shareholders, Hyderabad NCLT, and other regulatory clearances.

Capital restructuring mechanics

• Cancellation of 56,37,940 Rs 2 shares pro-rata.
• Paid-up capital reduced from Rs 2,05,01,600 to Rs 92,25,720.
• Consolidation from 46,12,860 shares of Rs 2 to 9,22,572 shares of Rs 10.
• Record date yields 9 new Rs 10 shares for every 100 old Rs 2 shares.
• Rs 1,12,75,880 accumulated losses offset against reduced capital.
• Promoter forgoes rounding-related share increase; post-restructure capital remains Rs 92,25,720.
• Shareholding percentages of continuing shareholders remain unchanged.

Regulatory filings and AGM

• AGM for FY 2025-26 convened; Annexure-A disclosed under Regulation 30.
• Scheme to be filed with BSE and hosted on company website after filing.

Hindustan Bio Sciences Ltd: Board Meeting filing summary

Results & AGM

• Board approves unaudited standalone results for quarter ended 30 June 2026.
• Limited Review Report issued by statutory auditors.
• 34th AGM fixed for 30 September 2026 at 10:00 AM.
• Notice, Directors' Report and Corporate Governance Report approved.
• Mr. VBSS Prasad appointed Scrutinizer for remote e-voting.
• Single segment: Trading of Pharmaceuticals.
• Earnings per equity share for continuing operations negative.
• Auditor's review: no material misstatement identified.

Dematerialisation activity

• RTA reports no dematerialisation certificates received for Hindustan Bio Sciences Ltd from April 2026 to June 2026.
• No dematerialisation/rematerialisation activities occurred in the quarter ended 30 June 2026.